@article{ec6cad827c8f457db28fd453f3580685,
title = "Neuroscience-based Nomenclature: What is it, why is it needed, and what comes next?",
author = "Hiroyuki Uchida",
note = "Funding Information: Dr Uchida has received grants from Eisai, Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Mochida Pharmaceutical, Meiji-Seika Pharmaceutical, and Novartis; speaker{\textquoteright}s honoraria from Otsuka Pharmaceutical, Eli Lilly, Shionogi, Pfizer, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, MSD, and Janssen Pharmaceutical; and advisory panel payments from Dainippon-Sumitomo Pharma within the past 3 years.",
year = "2018",
month = feb,
doi = "10.1111/pcn.12615",
language = "English",
volume = "72",
pages = "50--51",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "2",
}
